Evidence map›Paper›PMID 41339563›Full record

ArticleAnnals of surgical oncology2026

The Effect of Pelvic Lymph Node Dissection on Cancer-Specific Mortality in Partial Cystectomy According to Eligibility Criteria.

Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Andrea Marmiroli, Michele Nicolazzini, Calogero Catanzaro, Federico Polverino, Jordan A Goyal, Markus Graefen, Matteo Ferro and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific Mortality.International journal of urology : official journal of the Japanese Urological Association · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mattia LongoniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. longoni.mattia@hsr.it.ORCID http://orcid.org/0000-0002-2613-2306
Quynh Chi LeCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Fabian FalkenbachCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Andrea MarmiroliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Federico PolverinoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Markus GraefenDepartment of Urology, Goethe University, University Hospital, FrankfurtFrankfurt am Main, Germany.
Matteo FerroUnit of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
Felix K H ChunDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Carlotta PalumboDivision of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
Riccardo SchiavinaDepartment of Urology, University of Bologna, St. Orsola-Malpighi Hospital, Bologna, Italy.
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Shahrokh F ShariatDepartment of Urology, Weill Cornell Medical College, New York, NY, USA.
Leonardo QuartaDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Marco MoschiniDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Giorgio GandagliaDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Francesco MontorsiDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Alberto BrigantiDivision of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study tested the rates of partial cystectomy (PC) according to PC eligibility criteria (  ≤  cT2 stage, tumor   ≤  3 cm, and segmental resection possible), as well as the effect of pelvic lymph node dissection (PLND) at PC on cancer-specific mortality (CSM).

methodsIn the Surveillance, Epidemiology, and End Results (SEER) database (2004-2021), the study identified PC patients according to eligibility criteria and PLND status. Kaplan-Meier (KM) and multivariable Cox regression models (CRMs) addressed CSM after inverse probability of treatment-weighting (IPTW) for age, sex, race, household income, and T stage.

resultsOf 2078 PC patients, only 492 (23.7%) fulfilled all three PC criteria. The remaining 1586 patients fulfilled only two (n = 858, 41.3%), one (n = 614, 29.5%), or none (n = 114, 5.5%) of the three criteria. Overall, 790 (49.8%) patients underwent PLND, with PLND performed for 191 (38.8%) patients who fulfilled all three criteria versus 395 (46.0%) who fulfilled two versus 322 (52.4%) who fulfilled one versus 73 (64.0%) who fulfilled no criteria. After IPTW adjustment addressing all 2078 PC patients, 5 year CSM rates were 69.7% with PLND versus 64.2% without PLND (multivariable hazard ratio [mHR], 0.65; 95% confidence interval [CI], 0.54-0.77; p < 0.001). Conversely, for the 492 patients who fulfilled all three PC criteria, the 5 year CSM rates were 83.2% versus 81.8% (mHR, 0.76; 95% CI, 0.46-1.26, p = 0.3). Finally, for the 1586 patients who did not fulfill all three criteria, the 5 year CSM rates were 66.6% versus 58.0% (mHR, 0.69; 95% CI, 0.57-0.84; p < 0.001).

conclusionOnly a small minority of PC patients met all three eligibility criteria, exhibiting the most favorable survival. For those individuals, PLND had no effect on CSM. Conversely, for the majority of PC patients who did not fulfill all three criteria, PLND independently predicted significantly lower CSM.

Indexed as

CystectomyLymph Node ExcisionLymph NodesUrinary Bladder NeoplasmsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPelvisPrognosisSEER ProgramSurvival RateBladder cancerBladder-sparing surgeryNCCN guidelinesPartial cystectomyRadical cystectomy

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.